Patents by Inventor Ethan Sternberg

Ethan Sternberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070191329
    Abstract: New compounds useful in photodynamic therapy are of the formula and their 1,4-diene isomers and the metallated and/or labeled and/or conjugated forms thereof wherein each R1 is independently alkyl(1-6C); each n is independently an integer of 0-6; and R2 is vinyl or a derivative form thereof.
    Type: Application
    Filed: September 20, 2006
    Publication date: August 16, 2007
    Applicant: QLT Inc.
    Inventors: Ethan Sternberg, David Dolphin, Julia Levy, Anna Richter, David Hunt, Ashok Jain, Elizabeth Waterfield, Ronald Boch, Andrew Tovey
  • Publication number: 20050032769
    Abstract: New compounds useful in photodynamic therapy are of the formula and their 1,4-diene isomers and the metallated and/or labeled and/or conjugated forms thereof wherein each R1 is independently alkyl (1-6C); each n is independently an integer of 0-6; and R2 is vinyl or a derivative form thereof.
    Type: Application
    Filed: April 14, 2004
    Publication date: February 10, 2005
    Inventors: Ethan Sternberg, David Dolphin, Julia Levy, Anna Richter, David Hunt, Ashok Jain, Elizabeth Waterfield, Ronald Boch, Andrew Tovey
  • Patent number: 6756396
    Abstract: New compounds useful in photodynamic therapy are of the formula and their 1,4-diene isomers and the metallated and/or labeled and/or conjugated forms thereof wherein each R1 is independently alkyl (1-6C); each n is independently an integer of 0-6; and R2 is vinyl or a derivative form thereof.
    Type: Grant
    Filed: June 6, 2000
    Date of Patent: June 29, 2004
    Assignees: QLT Inc., The University of British Columbia
    Inventors: Ethan Sternberg, David Dolphin, Julia G. Levy, Anna M. Richter, David W. C. Hunt, Ashok Jain, Elizabeth M. Waterfield, Ronald E. Boch
  • Patent number: 6153639
    Abstract: New compounds useful in photodynamic therapy are of the formula ##STR1## and their 1,4-diene isomers and the metallated and/or labeled and/or conjugated forms thereofwherein each R.sup.1 is independently alkyl (1-6C);each n is independently an integer of 0-6; andR.sup.2 is vinyl or a derivative form thereof.
    Type: Grant
    Filed: May 17, 1999
    Date of Patent: November 28, 2000
    Assignees: QLT PhotoTherapeutices Inc., The University of British Columbia
    Inventors: Ethan Sternberg, David Dolphin, Julia G. Levy, Anna M. Richter, David W. C. Hunt, Ashok Jain, Elizabeth M. Waterfield, Ronald E. Boch
  • Patent number: 5929105
    Abstract: New compounds useful in photodynamic therapy are of the formula ##STR1## and their 1,4-diene isomers and the metallated and/or labeled and/or conjugated forms thereofwherein each R.sup.1 is independently alkyl (1-6C);each n is independently an integer of 0-6; andR.sup.2 is vinyl or a derivative form thereof.
    Type: Grant
    Filed: June 1, 1998
    Date of Patent: July 27, 1999
    Assignees: QLTPhoto Therapeutics, Inc., The University of British Columbia
    Inventors: Ethan Sternberg, David Dolphin, Julia G. Levy, Anna M. Richter, David W. C. Hunt, Ashok Jain
  • Patent number: 5399583
    Abstract: A group of hydro-monobenzoporphyrins "green porphyrins" (Gp) having absorption maxima in the range of 670-780 nanometers is useful in treating disorders or conditions which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light, or in treating virus, cells and tissues generally to destroy unwanted targets. The use of the Gp of the invention permits the irradiation for therapy to use wavelengths other than those absorbed by blood. The Gp of the invention may also be conjugated to ligands specific for receptor or to specific immunoglobulins or fragments thereof to target specific tissues or cells for the radiation treatment. Use of these materials permits lower levels of drug to be used, thus preventing side reactions which might destroy normal tissues.
    Type: Grant
    Filed: January 25, 1994
    Date of Patent: March 21, 1995
    Assignee: The University of British Columbia
    Inventors: Julia G. Levy, David Dolphin, Jack J. Chow, Ethan Sternberg
  • Patent number: 5283255
    Abstract: A group of hydro-monobenzoporphyrins "green porphyrins" (Gp) having absorption maxima in the range of 670-780 nanometers is useful in treating disorders or conditions which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light, or in treating virus, cells and tissues generally to destroy unwanted targets. The use of the Gp of the invention permits the irradiation for therapy to use wavelengths other than those absorbed by blood. The Gp of the invention may also be conjugated to ligands specific for receptor or to specific immunoglobulins or fragments thereof to target specific tissues or cells for the radiation treatment. Use of these materials permits lower levels of drug to be used, thus preventing side reactions which might destroy normal tissues.
    Type: Grant
    Filed: September 11, 1992
    Date of Patent: February 1, 1994
    Assignee: The University of British Columbia
    Inventors: Julia G. Levy, David Dolphin, Jack J. Chow, Ethan Sternberg
  • Patent number: 5171749
    Abstract: A group of hydro-monobenzoporphyrins "green porphyrins" (Gp) having absorption maxima in the range of 670-780 nanometers is useful in treating disorders or conditions which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light, or in treating virus, cells and tissues generally to destroy unwanted targets. The use of the Gp of the invention permits the irradiation for therapy to use wavelengths other than those absorbed by blood. The Gp of the invention may also be conjugated to ligands specific for receptor or to specific immunoglobulins or fragments thereof to target specific tissues or cells for the radiation treatment. Use of these materials permits lower levels of drug to be used, thus preventing side reactions which might destroy normal tissues.
    Type: Grant
    Filed: June 20, 1991
    Date of Patent: December 15, 1992
    Assignee: University of British Columbia
    Inventors: Julia G. Levy, David Dolphin, Jack J. Chow, Ethan Sternberg
  • Patent number: 5095030
    Abstract: A group of hydro-monobenzoporphyrins "green porphyrins" (Gp) having absorption maxima in the range of 670-780 nanometers is useful in treating disorders or conditions which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light, or in treating virus, cells and tissues generally to destroy unwanted targets. The use of the Gp of the invention permits the irradiation to use wavelengths other than those absorbed by blood. The Gp of the invention may also be conjugated to ligands specific for receptor or to specific immunoglobulins or fragments thereof to target specific tissues or cells for the radiation treatment. Use of these materials permits lower levels of drug to be used, thus preventing side reactions which might destroy normal tissues.
    Type: Grant
    Filed: September 28, 1989
    Date of Patent: March 10, 1992
    Assignee: University of British Columbia
    Inventors: Julia G. Levy, David Dolphin, Jack K. Chow, Ethan Sternberg
  • Patent number: 4920143
    Abstract: A group of hydro-monobenzoporphyrins "green porphyrins" (Gp) having absorption maxima in the range of 670-780 nanometers is useful in treating disorders or conditions which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light, or in treating virus, cells and tissues generally to destroy unwanted targets. The use of the Gp of the invention permits the irradiation to use wavelengths other than those absorbed by blood. The Gp of the invention may also be conjugated to ligands specific for receptor or to specific immunoglobulins or fragments thereof to target specific tissues or cells for the radiation treatment. Use of these materials permits lower levels of drug to be used, thus preventing side reactions which might destroy normal tissues.
    Type: Grant
    Filed: July 19, 1988
    Date of Patent: April 24, 1990
    Assignee: University of British Columbia
    Inventors: Julia G. Levy, David Dolphin, Jack K. Chow, Ethan Sternberg